Fiz, Francesco
Masci, Chiara
Costa, Guido
Sollini, Martina
Chiti, Arturo
Ieva, Francesca
Torzilli, Guido
Viganò, Luca
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (#2019-23822)
Article History
Received: 8 January 2022
Accepted: 11 March 2022
First Online: 26 March 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Humanitas Clinical and Research Hospital (date 23/02/2021: protocol number 5/21).
: Because of the retrospective nature of the analysis, the need for informed consent was waived.
: The authors declare no competing interests. Considering the conflicts of interest in general, we state that (1) L.V. received speaker’s honoraria from Johnson & Johnson; (2) A.C. received speaker’s honoraria from Advanced Accelerator Applications, General Electric Healthcare, Sirtex Medical Europe, and AmGen Europe; received travel grants from General Electric Healthcare and Sirtex Medical Europe; is a member of Blue Earth Diagnostics’ and Advanced Accelerator Applications’ advisory boards; and received scientific support, in terms of a 3-year Ph.D. fellowship, from the Sanofi Genzyme; (3) F.F. has been a consultant for the MSD Sharp & Dohme GmbH (LLC).The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.